NBTXR 3

Drug Profile

NBTXR 3

Alternative Names: Hafnium Oxide nanoparticles; NBTX 3; NBTXR-3; PEP-503

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nanobiotix
  • Developer Nanobiotix; PharmaEngine; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Radiosensitisers
  • Mechanism of Action Free radical stimulants; Radiography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase II/III Soft tissue sarcoma
  • Phase I/II Head and neck cancer; Prostate cancer; Rectal cancer
  • Preclinical Hepatocellular carcinoma; Lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 17 Apr 2018 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 10 Apr 2018 Preclinical trials in Lung cancer (Combination therapy) in USA (Intratumoural)
  • 30 Mar 2018 Nanobiotix plans a combination phase I/II trial of NBTXR 3 for Head and neck squamous cell carcinoma and Non-small cell lung cancer (Combination therapy, Metastatic disease, Recurrent) in USA in second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top